Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.
Analyst Ratings
This is a summary of recent ratings for Brainstorm Cell Therapeutics and Protara Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Brainstorm Cell Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Protara Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,798.73%. Protara Therapeutics has a consensus price target of $22.50, suggesting a potential upside of 409.05%. Given Brainstorm Cell Therapeutics’ higher probable upside, equities research analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Protara Therapeutics.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Brainstorm Cell Therapeutics | N/A | N/A | -528.56% |
Protara Therapeutics | N/A | -55.96% | -49.06% |
Institutional and Insider Ownership
14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Brainstorm Cell Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
Earnings and Valuation
This table compares Brainstorm Cell Therapeutics and Protara Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Brainstorm Cell Therapeutics | N/A | N/A | -$17.19 million | ($4.80) | -0.33 |
Protara Therapeutics | N/A | N/A | -$40.42 million | ($2.40) | -1.84 |
Protara Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Protara Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 10 factors compared between the two stocks.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.